Unknown

Dataset Information

Clinical implications of fracture severity risk with pioglitazone: a systematic review and meta-analysis of clinical randomized trials.


ABSTRACT:

Introduction

Pioglitazone, a thiazolidinedione, effectively reduces stroke and cardiovascular events in individuals with type 2 diabetes, insulin resistance, and/or stroke. However, its potential to increase fracture risk, particularly among women and those with pre-existing skeletal conditions, has not yet been completely understood. This meta-analysis aims to clarify fracture risk associated with pioglitazone, thereby focusing on individuals with a history of stroke.

Methods

A systematic review was performed for clinical trials conducted up to March 2024, focusing on trials comparing pioglitazone to placebo or other antihyperglycemic drugs that reported fracture outcomes.

Results

From 860 trials identified, 78 satisfied the inclusion criteria: 34 with a high risk of

SUBMITTER: Azhari HF 

PROVIDER: S-EPMC11922898 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature